Literature DB >> 16116973

Inhibitory effects of Celecoxib and Sc-58125 on proliferation of human carcinoma of larynx Hep-2 in vitro.

Juan Ding1, Qing Chang, Shusheng Gong.   

Abstract

The inhibitory effects of two kinds of selective cyclooxygenase-2 inhibitors on the proliferation of human carcinoma of larynx Hep-2 in vitro and their corresponding mechanisms were investigated. Hep-2 cells were cultured with two kinds of selective cyclooxygenase-2 inhibitors (Sc-58125 and Celecoxib) at various concentrations for 24 h. Morphological changes were observed under the phase microscopy and the growth suppression was detected by using MTT colorimetric assay. Apoptotic DNA fragments were observed by agarose gel electrophoresis, and the cell cycle and apoptotic rate were detected by flow cytometry (FCM) respectively. Hep-2 cells became rounded and detached from the culture dish after being treated with Celecoxib for 24 h, however, they remained morphologically unchanged with Sc-58125. Sc-58125 could increase G2 phase cells, whereas, Celecoxib rose G1 phase cells. Both of the two effects were dose-dependent. Moreover, the Hep-2 cells cultured with 50 micromol/L and 100 micromol/L Celecoxib showed obvious apoptosis, with the nuclear DNA of cells exhibiting characteristic DNA ladder. So Sc-58125 could inhibit the proliferation of Hep-2 cells by altering the G2 phase cells. However, Celecoxib had the same effect by changing the G1 phase cells and inducing apoptosis at higher concentration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116973     DOI: 10.1007/BF02873577

Source DB:  PubMed          Journal:  J Huazhong Univ Sci Technolog Med Sci        ISSN: 1672-0733


  6 in total

Review 1.  Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity?

Authors:  M Feldman; A T McMahon
Journal:  Ann Intern Med       Date:  2000-01-18       Impact factor: 25.391

2.  A cyclooxygenase-2 inhibitor (SC-58125) blocks growth of established human colon cancer xenografts.

Authors:  C S Williams; H Sheng; J A Brockman; R Armandla; J Shao; M K Washington; A G Elkahloun; R N DuBois
Journal:  Neoplasia       Date:  2001 Sep-Oct       Impact factor: 5.715

3.  Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.

Authors:  C D Morris; G R Armstrong; G Bigley; H Green; S E Attwood
Journal:  Am J Gastroenterol       Date:  2001-04       Impact factor: 10.864

4.  Nonsteroidal anti-inflammatory drugs and risk of digestive cancers at sites other than the large bowel.

Authors:  P F Coogan; L Rosenberg; J R Palmer; B L Strom; A G Zauber; P D Stolley; S Shapiro
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2000-01       Impact factor: 4.254

5.  Correlation of expression of cyclooxygenase-2, vascular endothelial growth factor, and peroxisome proliferator-activated receptor delta with head and neck squamous cell carcinoma.

Authors:  E C Jaeckel; S Raja; J Tan; S K Das; S K Dey; D A Girod; T T Tsue; T R Sanford
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2001-10

6.  COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib.

Authors:  S Grösch; I Tegeder; E Niederberger; L Bräutigam; G Geisslinger
Journal:  FASEB J       Date:  2001-10-15       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.